Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment
Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment
akero therapeutics開始進行Efruxifermin治療肝病的第三階段研究。
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the SYNCHRONY Outcomes study, a Phase 3 trial evaluating the efficacy and safety of efruxifermin (EFX) in patients with compensated cirrhosis, fibrosis stage 4 (F4) due to metabolic dysfunction-associated steatohepatitis (MASH).
Akero Therapeutics, Inc.（納斯達克股票代碼：AKRO）是一家開發革命性治療嚴重代謝性疾病的臨床階段公司，今天宣佈啓動 SYCHRONY 研究，這是一項第三階段試驗，評估營養不良相關的肝纖維化（NASH）患者的代償性肝硬化患者中，efruxifermin（EFX）的療效和安全性。研究是針對患有因MASH（F4纖維化）引起的代償性肝硬化患者進行的SYNCHRONY一項第三階段試驗SYNCHRONY研究，評估了代償性肝硬化和病變階段爲4級（F4）的營養不良相關肝纖維化（MASH）患者使用efruxifermin（EFX）的療效和安全性。
資訊熱榜
更新時間